Introduction
============

Neuroendocrine tumors (NETs), which account for \<1% of all malignant tumors, originate from disseminated neuroendocrine cells. Most NETs are found in the gastrointestinal and respiratory tracts ([@b1-ol-0-0-11101]). Neuroendocrine carcinomas (NECs) in the gastrointestinal tract are mostly found in the rectum, jejuno-ileum, and pancreas. Primary NEC of the gallbladder is a rare disease, it makes up 1.4% of all gastrointestinal endocrine tumors, and 0.4--4% of all malignant tumors that occur in the gallbladder ([@b2-ol-0-0-11101]). In general, somatostatin receptor scintigraphy (SRS) has a low diagnostic sensitivity for NECs and ^18^F fluorodeoxyglucose (FDG)-positron emission tomography (PET) is useful in the diagnosis of tumors with a high proliferation index and high glucose consumption.

Here, we report a case of a patient preoperatively diagnosed with gallbladder NEC using SRS.

Case presentation
=================

A 63-year-old man with no complaints visited a doctor for abdominal ultrasonography (AUS) screening. AUS revealed thickening of the gallbladder wall. The patient was therefore admitted to our hospital for further examination. He was taking medication for hypertension and type 2 diabetes and he had a family history of lung cancer.

Blood analysis at the time of admission revealed mild liver dysfunction. No elevation in the levels of tumor markers such as carcinoembryonic antigen (CEA), cancer antigen 19-9 (CA 19-9), neurospecific enolase (NSE), or pro-gastrin-releasing peptide was observed. There were no abnormalities in the levels of hormones such as insulin, glucagon, or gastrin ([Table I](#tI-ol-0-0-11101){ref-type="table"}--[V](#tV-ol-0-0-11101){ref-type="table"}). AUS showed a low-echoic mass (22×14 mm) with clear boundaries to the liver, protruding into the lumen from the gallbladder neck ([Fig. 1](#f1-ol-0-0-11101){ref-type="fig"}).

Abdominal contrast-enhanced computed tomography (CT) showed wall thickening that appeared to extend into the lumen of the gallbladder neck with a weak contrast effect. No obvious out-of-wall development was observed ([Fig. 2](#f2-ol-0-0-11101){ref-type="fig"}).

In abdominal magnetic resonance imaging (MRI), the tumor showed a low signal intensity on T1 imaging and a high signal intensity on T2 imaging that was slightly higher than the liver parenchyma. An apparent high diffusion signal was observed in diffusion-weighted imaging (DWI) and the signal declined with apparent diffusion coefficient mapping. The mucosal surface was preserved. These findings were indicative of a NET and a malignant lymphoma with higher cell density than that of a typical gallbladder cancer. Magnetic resonance cholangiopancreatography showed a defect in the neck of the gallbladder ([Fig. 3](#f3-ol-0-0-11101){ref-type="fig"}).

Endoscopic ultrasonography findings were similar to those of AUS and showed a structure of submucosal tumor-like appearance and clear boundaries to the liver. No Rokitansky-Aschoff sinus was observed. Endoscopic retrograde cholangiopancreatography showed a defect in the neck of the gallbladder and pancreaticobiliary malfunction was not observed. The amylase levels in the bile juice was not elevated. An endoscopic naso-gallbladder drainage catheter was placed in the gallbladder, and bile cytology, which was performed 4 times, revealed a large number of heterogeneous cell clusters. Adenocarcinoma was suspected based on these findings ([Fig. 4](#f4-ol-0-0-11101){ref-type="fig"}).

Positron emission tomography/computed tomography (PET/CT) revealed the abnormal accumulation of ^18^F fluorodeoxyglucose (FDG) in the gallbladder wall (Maximum standard uptake value: 5.8 → 8.8), with no findings suggestive of distant organ metastasis.

SRS was performed because gallbladder NET was also considered as a possible diagnosis. Abnormal accumulation was apparent in SRS and is consistent with a tumor. No other abnormal accumulation suggestive of metastasis was observed ([Fig. 5](#f5-ol-0-0-11101){ref-type="fig"}).

Gallbladder NEC was suspected based on the above findings. However, are suspected diagnosis was stage II gallbladder carcinoma based on the results of bile cytology. Therefore, we performed enlarged cholecystectomy and D2 lymphadenectomy.

A tumor (45×35 mm) stretching from the body to the neck of the gallbladder was found in the resected specimen. Hematoxylin and eosin staining showed that the tumor cells had honeycomb growth with a high nucleus-to-cytoplasm ratio, submucosal growth in the shape of a cord, and numerous mitotic figures (20/10 high power fields; [Fig. 6](#f6-ol-0-0-11101){ref-type="fig"}). In addition, Ki-67 labeling rate was \>80%. The tumor cells were positive for synaptophysin, chromogranin A, and cluster of differentiation 56 (CD56). Immunohistochemical staining for somatostatin receptor (SSTR) 2A was negative. Based on these findings, the patient was diagnosed with gallbladder NEC. A small differentiated tubular adenocarcinoma was found on the mucosal surface; however, this made up only about 10% of the overall tumor, which does not meet the diagnostic criteria for mixed adenoneuroendocrine carcinoma ([Fig. 7](#f7-ol-0-0-11101){ref-type="fig"}). The final pathological diagnosis was small cell NEC (pT3a, N, M0, stage II) Gbn, 45×35 mm, nodular-infiltrating type, circ, NEC, pT3a, int, INFb, ly1, v1, ne2, pCM0, pEM1, pR0. As multiple liver metastases were observed on CT 4 months after the operation, chemotherapy (CPT-11 \[irinotecan\] + cis-diamminedichloroplatinum \[cisplatin\]) was administered according to the regimen for small cell carcinoma of the lung. The patient is still undergoing treatment.

SSTR5 immunostaining was performed to elucidate why SRS was positive when SSTR2 immunostaining was negative, but we obtained a negative result. Additionally, we measured gene expression using quantitative real-time polymerase chain reaction (PCR) for all subtypes of SSTR (SSTR1-5) and compared our results with those of earlier studies that reported on the Caco2 cell line ([@b3-ol-0-0-11101]--[@b5-ol-0-0-11101]). The tumor was positive for all SSTR subtypes ([Fig. 8](#f8-ol-0-0-11101){ref-type="fig"}) and may express SSTRs other than SSTR2 and SSTR5.

The study was approved by the ethics committee of Kagoshima University Hospital (approved number 26-6).

Discussion
==========

Here, we report a rare case of gallbladder NEC preoperatively diagnosed using SRS. NETs occur in the gastrointestinal tract and bronchopulmonary system. Primary NEC of the gallbladder is a rare disease, accounting for only up to 1.4% of all gastrointestinal endocrine tumors and 0.4--4% of all malignant gallbladder tumors. In addition, the mean age of patients at disease onset is 64 years, and the incidence in females is relatively high (70%). Gallbladder NEC is characterized by rapid development, early liver metastasis, lymph node metastasis, and direct metastasis, and the prognosis is considered to be extremely poor ([@b2-ol-0-0-11101],[@b6-ol-0-0-11101],[@b7-ol-0-0-11101]). According to the 2010 World Health Organization classification of tumors of the digestive tract, NETs are categorized into NET G1, NET G2, and NECs according to mitotic count and Ki-67 index ([@b8-ol-0-0-11101]). NEC is difficult to preoperatively differentiate from gallbladder adenocarcinoma, and most patients are diagnosed postoperatively by immunostaining for markers such as NSE, CD56, chromogranin A, and synaptophysin ([@b9-ol-0-0-11101]). Several hypotheses have been proposed on the pathogenesis of gallbladder NETs. A previous report posited that NETs are derived from undifferentiated pluripotent cells at the site of development, which are capable of differentiating into epithelial and neuroendocrine cells, and that this ability to differentiate changes during cancer proliferation and leads to a shift to small cell carcinoma ([@b10-ol-0-0-11101]).

No specific imaging features of gallbladder NECs have been described ([@b11-ol-0-0-11101],[@b12-ol-0-0-11101]). Many cases are difficult to distinguish from typical, more common gallbladder cancers. DWI in MRI has been reported to be useful for classifying NEC and adenocarcinoma components. As NECs have a higher proliferative potential than typical cancers and a high cell density, they have a relatively low diffusion ability ([@b13-ol-0-0-11101]). The gallbladder NEC in our patient had a high diffusion signal on DWI. DWI is considered potentially useful for differentiating between benign gallbladder tumors, typical gallbladder cancers, and gallbladder NECs ([@b14-ol-0-0-11101]).

SRS using ^111^In-pentetreotide, which targets somatostatin receptors (SSTRs) and has a high affinity for subtype 2A, is currently the gold standard functional imaging test for NETs ([@b15-ol-0-0-11101]). For the diagnosis of NETs, European and US guidelines recommend focal diagnosis using SRS, diagnosis of lymph node and liver metastases, and CT and MRI. The evaluation of SSTRs has also been reported to be useful for predicting therapeutic response to octreotide preparations ([@b16-ol-0-0-11101]). While SRS has a low diagnostic sensitivity for poorly differentiated NECs, FDG-PET is useful for the diagnosis of tumors with a high proliferation index. The diagnostic sensitivity is low for NETs with low proliferation index, slow growth rate, and low glucose consumption ([@b17-ol-0-0-11101],[@b18-ol-0-0-11101]). Although pathological examination revealed a poorly differentiated small cell NET in our patient, SRS and FDG-PET results were positive. In NETs, the lower the degree of differentiation, the lower the rate of SRS positivity and the higher the degree of PET accumulation. However, a comparative study reported that tumors with proliferation (Ki-67) indices \>15 and \<2% had positive SRS sensitivities of 69 and 87%, respectively. This suggests the possibility of SRS accumulation, even in NECs ([@b17-ol-0-0-11101]).

SSTRs, which are receptors of the peptide hormone somatostatin, have 5 subtypes, namely SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5. ^111^In-pentetreotide has an affinity for SSTR2 and SSTR5. Generally, most NETs express SSTR2, and SRS is considered to be useful in the diagnosis of NETs ([@b19-ol-0-0-11101]). In NETs, the expression of SSTR2 decreases as the degree of differentiation decreases. In the case of our patient, immunohistochemical staining was negative for SSTR2A and SSTR5; however, real-time PCR detected the expressions of all the subtypes (SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5; [Fig. 8](#f8-ol-0-0-11101){ref-type="fig"}). SRS has a high affinity for SSTR2, SSTR5, and SSTR3. We postulated that the real-time PCR result, which suggested that, besides SSTR2 and SSTR5, the tumor may also express other SSTRs such as SSTR3, may explain the discrepancy between the loss of SSTR expression shown on immunohistochemistry and the apparent accumulation in the tumor shown on SRS. SRS may be useful for NEC diagnosis in some cases, even when immunohistochemical staining for SSTRs is negative.

Several limitations associated with the present study warrant mention. First, we performed immunohistochemical staining for SSTR2 and SSTR5 but not for SSTR1, SSTR3, and SSTR4, because we did not obtain antibodies against these subtypes. Second, we detected the expressions of SSTR1, SSTR2, SSTR3, SSTR4, and SSTR5 using real-time PCR ([Fig. 8](#f8-ol-0-0-11101){ref-type="fig"}) and compared our findings with those of earlier studies that reported on the Caco2 cell line ([@b4-ol-0-0-11101],[@b5-ol-0-0-11101]). Owing to the lack of tissue, we were not able to compare SSTR mRNA expression between the tumor and the adjacent normal tissue.

In conclusion, gallbladder NEC is a rare disease and is difficult to diagnose preoperatively. The incidence of this disease may increase in the future, and accurate diagnostic and effective treatment methods, which may include surgery and chemotherapy, must be established to improve prognosis. Gallbladder NET should be considered and SRS should be performed when evaluation of an advanced gallbladder tumor reveals normal levels of tumor markers, such as CEA and CA19-9, and atypical gallbladder tumor characteristics on imaging, such as apparent high diffusion signal on DWI.
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![AUS showing thickened gallbladder wall and a structure of submucosal tumor-like appearance. Slight blood flow is detected on a Doppler ultrasound. AUS, abdominal ultrasonography.](ol-19-01-0247-g00){#f1-ol-0-0-11101}

![Abdominal contrast-enhanced computed tomography showing the thickened wall of the neck of the gallbladder and a slightly contrasted tumor. (A) Early arterial phase, (B) late arterial phase, (C) portal phase and (D) equilibrium phase. Yellow arrow, tumor site.](ol-19-01-0247-g01){#f2-ol-0-0-11101}

![Abdominal gadolinium-ethoxybenzyl-enhanced MRI. (A) Tumor shows a low T1 signal (arrow), (B) a slightly high T2 signal (arrow), (C) an apparent high diffusion signal on diffusion-weighted imaging, (D) A signal that declined with apparent diffusion coefficient mapping, (E) ethoxybenzyl-enhanced MRI showing wall thickening that appear to extend into the lumen of the gallbladder and (F) magnetic resonance cholangiopancreatography indicating a defect in the gallbladder neck. Yellow arrow, tumor site.](ol-19-01-0247-g02){#f3-ol-0-0-11101}

![EUS showing a structure of submucosal tumor-like appearance with clear boundaries to the liver. (A) EUS B mode, (B) doppler mode, (C) ERCP showing a defect in the neck of the gallbladder (arrow) and (D) bile cytology. (A, B) No signs of Rokitansky-Aschoff sinus or calcification were indicated. The amylase level in the bile was not elevated (amylase; 397 U/L). (D) An endoscopic naso-gallbladder drainage catheter is placed in the gall bladder and bile cytology is performed. The cytological diagnosis is suspected adenocarcinoma. EUS, Endoscopic ultrasonography; ERCP, endoscopic retrograde cholangiopancreatography.](ol-19-01-0247-g03){#f4-ol-0-0-11101}

![PET and SRS. (A) PET. SRS (B) horizontal image and (C) vertical axis image (arrow). Abnormal accumulation is apparent and is consistent with a tumor on PET and SRS. PET, positron emission tomography; SRS, somatostatin receptor scintigraphy.](ol-19-01-0247-g04){#f5-ol-0-0-11101}

![Pathological analysis. (A) Macroscopic features of the resected gallbladder. The tumor is a small cell neuroendocrine tumor (B) Hematoxylin and eosin staining (magnification, ×4) and (C) nuclear fission (arrow; magnification ×400).](ol-19-01-0247-g05){#f6-ol-0-0-11101}

![Immunohistochemical staining. (A) Synaptophysin, (B) Chromogranin A, (C) Cluster of differentiation 56 (CD56), (D) Ki-67, (E) SSTR2 and (F) SSTR5. The tumor cells in the gallbladder are positive for synaptophysin (A) chromogranin A (B) and CD56 (C) Over 80% of the cells are positive for (D) Ki-67. The tumor cells are negative for (E) SSTR2 and (F) SSTR5 (F) All, magnification ×40. CD56, cluster of differentiation 56; SSTR, somatostatin receptors.](ol-19-01-0247-g06){#f7-ol-0-0-11101}

![Reverse transcription-quantitative PCR for the measurement of the gene expression of all SSTR subtypes (SSTR1-5). SSTR, somatostatin receptors.](ol-19-01-0247-g07){#f8-ol-0-0-11101}

###### 

Hematology.

  Hematology   Result       Unit
  ------------ ------------ ------
  WBC          3710         /µl
    Lymph      25.3         \%
    Mono       4.9          \%
    Eosino     1.1          \%
    Baso       0.3          \%
    Neut       68.4         \%
  RBC          543×10^4^    /µl
  Hb           14.6         g/dl
  Hct          44.2         \%
  Plt          16.3×10^4^   /µl

WBC, White blood cells; Lymph, Lymphocytes; Mono, Monocytes; Eosino, Eosinocytes; Baso, Basophils; Neutro, Neutrophils; RBC, Red blood cells; Hb, Hemoglobin; Hct, Hematocrit; Plt, Platelets.

###### 

Coagulation.

  Coagulation   Result   Unit
  ------------- -------- -------
  PT            118      \%
  D-Dimer       \<0.5    µg/ml
  FDP           3.1      µg/ml

PT, Prothrombin time; FDP, Fibrin degradation products.

###### 

Serum chemistry.

  Serum chemistry   Results   Unit
  ----------------- --------- -------
  AST               35        IU/ l
  ALT               46        IU/ l
  LDH               192       IU/ l
  ALP               122       IU/ l
  γ-GTP             43        IU/ l
  T-Bil             0.8       mg/dl
  D-Bil             \<0.03    mg/dl
  TP                7.3       g/dl
  ALB               4.8       g/dl
  BUN               14.5      mg/dl
  Cre               0.91      mg/dl
  Na                138       mEq/l
  K                 4.5       mEq/l
  Cl                104       mEq/l
  Ca                9.5       mEq/l
  CRP               0.03      mg/dl

AST, Aspartate transaminase; ALT, Alanine aminotransferase; LDH, Lactate dehydrogenase; ALP, Alkaline phosphatase; γ-GTP, γ-Glutamyl transpeptidase; T-Bil, Total bilirubin; D-Bil, Direct bilirubin; TP, Total protein; ALB, Albumin; BUN, Blood urea nitrogen; Cre, Creatinine; CRP, C-reactive protein.

###### 

Tumor markers.

  Tumor markers   Results   Unit
  --------------- --------- -------
  CEA             1.5       ng/ml
  CA19-9          8.7       U/ml
  NSE             13.6      ng/ml
  ProGRP          27.6      pg/ml

CEA, Carcinoembryonic antigen; CA19-9, carbohydrate antigen; NSE, Neuron-specific enolase; ProGR, gastrin releasing peptide.

###### 

Hormones.

  Hormones   Result   Unit
  ---------- -------- -------
  Insulin    11.3     µU/ml
  Glucagon   174      pg/ml
  Gastrin    91       pg/ml
